Effect of metabolic dysfunction on the risk of liver-related events in patients cured of hepatitis C virus DOI Open Access
Wei‐Fan Hsu, Hsueh‐Chou Lai, Sheng‐Hung Chen

et al.

American Journal of Cancer Research, Journal Year: 2024, Volume and Issue: 14(4), P. 1914 - 1925

Published: Jan. 1, 2024

The impact of metabolic dysfunction or dysfunction-associated fatty liver disease (MAFLD) on liver-related events (LREs) in patients with chronic hepatitis C (CHC) who had achieved a sustained virologic response (SVR) to direct-acting antiviral agents (DAAs) is unknown.A total 924 cured CHC and documented body mass index (BMI) were included the analysis, data period was from September 2012 April 2022.Hepatic steatosis identified either through ultrasonography blood biomarkers.Metabolic defined as presence overweight obesity (BMI ≥ 23 kg/m 2 ), type diabetes mellitus (DM), dysregulation.Patients may have more than one dysfunction.Variables at 12 24 weeks after DAA therapy (PW12) used identify predictors LREs.The median age 58 (49-65) years.Of participants, 418 (45.2%) male.The BMI 24.01 (21.78-26.73)kg/m , 174 (18.8%) DM.A multivariable Cox regression analysis revealed that age, male, albumin, bilirubin, alphafetoprotein (AFP), (hazard ratio: 1.709, 95% confidence interval: 1.128-2.591,P = .011),and FIB-4 > 3.25 independent LREs.Type DM dysregulation exhibited larger time-dependent area under receiver operating characteristic curve for LREs did obesity.Moreover, be an predictor hepatocellular carcinoma.Metabolic increased risk HCC SVR therapy.

Language: Английский

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease DOI Creative Commons
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu

et al.

Hepatology International, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Language: Английский

Citations

5
Chronic Hepatitis C Related Steatotic Liver Disease Is More Than “Miscellaneous Steatotic Liver Disease” DOI
Chung‐Feng Huang,

Ming-Lun Yeh,

Chia‐Yen Dai

et al.

Clinical Gastroenterology and Hepatology, Journal Year: 2024, Volume and Issue: 22(10), P. 2137 - 2139.e2

Published: May 9, 2024

Language: Английский

Citations

4
Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis DOI Creative Commons
Chung‐Feng Huang, Po‐Cheng Liang, Chih‐Wen Wang

et al.

The Kaohsiung Journal of Medical Sciences, Journal Year: 2024, Volume and Issue: 40(4), P. 374 - 383

Published: Jan. 17, 2024

Abstract The accuracy of noninvasive seromarkers in predicting liver fibrosis metabolic dysfunction‐associated fatty disease (MAFLD) patients with or without viral hepatitis is elusive. AST to platelet ratio index (APRI), fibrosis‐4 (FIB‐4), and NAFLD score (NFS) were assessed 871 MAFLD who received elastography a hepatitis‐endemic area. area under the receiver operating characteristic (AUROC) curve increased substantially increasing fibrotic stage across three biomarkers. APRI (AUROC range 0.73–0.80) FIB‐4 0.66–0.82) performed better than NFS 0.63–0.75). When divided into non‐viral groups, AUROC (range 0.76–0.80) 0.68–0.78) 0.62–70) existed only MALFD but not MAFLD. Regarding NFS, was higher 0.69–0.86) outperformed at all stages. advancement for exerted diagnostic different best 91.1% using cutoff value −9.98 cirrhosis patients. as whole. suboptimal performance Caution should be taken when assessing hepatitis.

Language: Английский

Citations

2
Effect of metabolic dysfunction on the risk of liver-related events in patients cured of hepatitis C virus DOI Open Access
Wei‐Fan Hsu, Hsueh‐Chou Lai, Sheng‐Hung Chen

et al.

American Journal of Cancer Research, Journal Year: 2024, Volume and Issue: 14(4), P. 1914 - 1925

Published: Jan. 1, 2024

The impact of metabolic dysfunction or dysfunction-associated fatty liver disease (MAFLD) on liver-related events (LREs) in patients with chronic hepatitis C (CHC) who had achieved a sustained virologic response (SVR) to direct-acting antiviral agents (DAAs) is unknown.A total 924 cured CHC and documented body mass index (BMI) were included the analysis, data period was from September 2012 April 2022.Hepatic steatosis identified either through ultrasonography blood biomarkers.Metabolic defined as presence overweight obesity (BMI ≥ 23 kg/m 2 ), type diabetes mellitus (DM), dysregulation.Patients may have more than one dysfunction.Variables at 12 24 weeks after DAA therapy (PW12) used identify predictors LREs.The median age 58 (49-65) years.Of participants, 418 (45.2%) male.The BMI 24.01 (21.78-26.73)kg/m , 174 (18.8%) DM.A multivariable Cox regression analysis revealed that age, male, albumin, bilirubin, alphafetoprotein (AFP), (hazard ratio: 1.709, 95% confidence interval: 1.128-2.591,P = .011),and FIB-4 > 3.25 independent LREs.Type DM dysregulation exhibited larger time-dependent area under receiver operating characteristic curve for LREs did obesity.Moreover, be an predictor hepatocellular carcinoma.Metabolic increased risk HCC SVR therapy.

Language: Английский

Citations

1